ARTICLE | Company News
InterMune acquires Alza's Amphotec
January 10, 2001 8:00 AM UTC
ITMN acquired worldwide rights to AZA's Amphotec liposomal amphotericin B, which is marketed to treat invasive aspergillosis. AZA will receive a $9 million upfront license fee plus milestones based on...